Matched Aim 2 Cohort: No SLNB vs Matched Aim 2 Cohort: SLNB: Overall Survival
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.183 | 0.172 | 0.196 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.144 | 0.129 | 0.16 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0393 | 0.0193 | 0.0585 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.27 | 1.12 | 1.44 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.33 | 1.15 | 1.55 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Matched Aim 2 Cohort: No SLNB than on Matched Aim 2 Cohort: SLNB | 25.5 | 17.1 | 51.7 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Matched Aim 2 Cohort: No SLNB | The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2.The cohort population includes patients diagnosed at age 67-94 years with DCIS between January 2001 and December 2013, and had received BCS as their first surgery within 6 months of diagnosis.~Only those who did not receive sentinel lymph node biopsy (SLNB) were included (control group). | 727 | 3,965 | OG000 | ClinicalTrials.gov |
| Group 2 | Matched Aim 2 Cohort: SLNB | The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2.The cohort population includes patients diagnosed at age 67-94 years with DCIS between January 2001 and December 2013, and had received BCS as their first surgery within 6 months of diagnosis.~Only those who received sentinel lymph node biopsy (SLNB) were included (intervention group). | 287 | 1,992 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Overall Survival | ClinicalTrials.gov |
| Description | Secondary outcomes for Aim 2. | ClinicalTrials.gov |
| Time frame | From 9 months post-diagnosis to death/end of study period (up to 1.5 years) | ClinicalTrials.gov |
| Population | Mahalanobis matching was used to adjust for baseline characteristics and account for potential treatment selection bias, where those who receive SLNB might be systematically different from those who do not. Matches were assigned by choosing the two best non-SLNB patient matches for each SLNB patient. The final matched cohort was used for analyses. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ | ClinicalTrials.gov |
| NCT number | NCT02908178 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Ductal Carcinoma In Situ | ClinicalTrials.gov |
| Interventions | Sentinel lymph node biopsy (SLNB) | ClinicalTrials.gov |
| Lead sponsor | Yale University | ClinicalTrials.gov |
| Results first posted | 2019-04-30 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02908178?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.